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Purpose: This study sought to characterize the expression of angiogenesis-related genes in a mouse model of corneal
neovascularization, either untreated or after treatment with a single injection of bevacizumab by three different routes. In
addition, the effectiveness of the treatment was compared to a rabbit model.
Methods: A chemical burn was induced in the mid-cornea of the right eye in 119 mice; 56 of them were untreated and
63 were bevacizumab-treated. Neovascularization was evaluated 2, 4, 8, 10, and 14 days later using digital photos,
angiography and India ink perfusion. The relative area of new blood vessels was analyzed using slit-lamp examination in
vivo and on histological and flat-mount sections. The levels of gene expression involved in the angiogenic process vascular
endothelial growth factor [VEGF], insulin-like growth factor-1 [IGF-1], pigment epithelium derived factor [PEDF], and
macrophage-inflammatory protein-2 [MIP-2]) were measured by a real-time polymerase chain reaction. Six rabbits
underwent the same injury and treatment, and the response was compared to the mouse model.
Results: Neovascularization was first observed two days after injury. The affected section increased from 11.24% (±7.0)
of the corneal area to 47.42% (±25.4) on day 8 and 50.62% (±24.7) on day 10. In the mice treated with bevacizumab, the
relative area of neovascularization was significantly lower at the peak time points (p<0.005): 24.90% (±21.8) on day 8
and 28.29% (±20.9) on day 10. Spontaneous regression was observed on day 14 in both groups, to 26.98% (±19.9) in the
untreated mice and 10.97% (±10.8) in the bevacizumab-treated mice (p<0.005). Rabbits also showed peak corneal
neovascularization on days 8-10, with significant regression of the vessels following intracameral bevacizumab injection.
In the mice, intraocular (intravitreal, intracameral) injection was more effective than subconjuctival injection. VEGF gene
expression was upregulated in both the untreated and treated mice, but was slightly less in the treated mice. PEDF gene
expression decreased in both the treated and untreated mice. In the untreated group, gene expression peaked (above
baseline) at 14 days, and in the untreated mice, it had already peaked by day 8. IGF-1 was upregulated early in the model;
at 8 days, there was only a slight change in the untreated group compared to a significant increase in the treated group.
MIP-2 was upregulated in both groups in the early stage and returned to baseline on day 14.
Conclusions: Bevacizumab treatment partially inhibits the progressive corneal neovascularization induced by chemical
damage in a mouse model. Treatment is more effective when administered via the intraocular than the subconjunctival
route. The clinical findings are compatible with the angiographic and histologic data and are supported by molecular
analysis showing a partial change in expression of proangiogenic genes. The molecular mechanisms involved in corneal
neovascularization  and  inflammation  warrant  further  exploration.  These  findings  may  have  important  therapeutic
implications in the clinical setting.
Angiogenesis  is  one  of  the  key  factors  in  tumor
progression and metastasis. Anti-angiogenic therapy inhibits
tumor angiogenesis and promotes apoptosis of existing blood
vessels, thereby intercepting the tumor's supply of oxygen and
nutrients. Furthermore, by normalizing vascular permeability,
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anti-angiogenic  therapy  can  improve  the  delivery  of
therapeutic agents to tumor cells.
A normal, healthy cornea is devoid of both blood and
lymphatic vessels [1-3], but inflammatory conditions such as
chemical burns, trauma or infection can cause angiogenesis
[4-6]. The development of new blood vessels in the cornea,
called neovascularization, is a final pathway common to all
insults that are resistant to treatment and may lead to severe
impairment of vision. Corneal neovascularization has been
reported  in  4.14%  of  patients  presenting  for  general
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2326ophthalmologic care in the USA, representing an estimated
1.4 million individuals [7].
Until recently, the mainstay of anti-angiogenic therapy in
the  cornea  was  nonspecific  anti-inflammatory  drugs  and
sometimes  anti-angiogenic  steroids,  but  they  were  often
unable to prevent or stop neovascularization [8]. Even surgical
treatment with corneal transplantation frequently failed, as the
new vessels induced an inflammatory rejection of the graft
[7,9]. However, the rapid progress in angiogenesis research in
the last few years has led to the development of several novel,
specific anti-angiogenic drugs for use in both oncology and
ophthalmology [10]. As the vast majority of these agents are
low-molecular-weight  compounds  with  a  poor
pharmacokinetic profile and rapid clearance rate, researchers
have found that by conjugating them to polymeric carriers,
their solubility and specificity may be increased and their
pharmacokinetics  is  improved  [11,12].  Recent  reports
describe  the  development  of  polymeric  nanospheres  that
selectively target the activated vascular endothelium and can
deliver  encapsulated  anti-angiogenic  agents  in  cases  of
inflammatory disease with an angiogenic component [13].
A  major  focus  of  the  research  into  anti-angiogenic
therapy is vascular endothelial growth factor (VEGF), which
is known to promote several steps in angiogenesis, including
proteolytic  activities,  endothelial  cell  proliferation,
endothelial cell migration and capillary tube formation [6]. Its
essential  role  in  normal  embryonic  vasculogenesis  and
angiogenesis was supported by findings that inactivation of a
single VEGF allele in mice resulted in death of the embryo
[14]. VEGF exerts its activity by binding to several high-
affinity transmembrane endothelial cell receptors, especially
VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). This leads to
intracellular receptor phosphorylation, which in turn triggers
the  relevant  intracellular  downstream  receptor  pathways
[15].  VEGF  has  been  found  to  play  a  role  in  corneal
neovascularization in both experimental models and humans
[16-18]. Measurements of VEGF molecules and receptors in
diseased corneas yielded higher concentrations than in normal
or avascular abnormal corneas. Treatment strategies targeting
the VEGF signaling pathway include anti-VEGF antibodies,
soluble receptors binding directly to the VEGF ligand, anti-
VEGF receptor (VEGFR) antibodies and VEGFR tyrosine
kinase  inhibitors.  Anti-VEGF  therapy  has  proven  highly
effective in treating advanced colon cancer and is currently
being tested in gastric cancer [19]. In several studies, the
manipulation of various anti-VEGF agents led to effective
inhibition of corneal neovascularization [3,20].
Bevacizumab (Avastin; Genentech, San Francisco, CA)
is a full-length recombinant humanized murine monoclonal
antibody that binds to and inhibits the biological activity of
all  five  human  VEGF-A  isoforms:  VEGF115,  VEGF121,
VEGF165, VEGF189, and VEGF206 [21]. It prevents VEGF-
A from ligating to its endothelial receptors, VEGFR-1 and
VEGFR-2 [22,23], but does not neutralize other members of
the  VEGF  gene  family,  such  as  VEGF-B  or  VEGF-C
[24-26]. The antibody was engineered by assembling VEGF-
A binding residues from the murine-neutralizing antibody into
the  framework  of  a  human  immunoglobulin  [27].
Bevacizumab has been approved by the US Food and Drug
Administration  for  use  in  the  treatment  of  metastatic
colorectal cancer. Since mid-2005, it has been applied off-
label  in  the  treatment  of  ocular  disease  and  has  shown
promising  short-term  results  in  alleviating  intraocular
neovascular conditions [28-30].
Reports that the systemic application of bevacizumab in
animal  models  inhibited  inflammatory  corneal
neovascularization  [20,23]  led  to  the  assumption  that
bevacizumab might also be clinically beneficial in patients
who do not respond to conventional steroid therapy. This was
followed by successful experiences with bevacizumab applied
as eye drops [31-33] or subconjunctivally [34-36] in patients
with  progressive  corneal  neovascularization.  Topical
treatment was found to be safe and efficient, without local or
systemic adverse effects [37,38]; some authors suggested that
it could serve as a pre-transplantation treatment option [39].
Further studies reported a reduction in corneal inflammation
and  choroidal  neovascularization  after  subconjunctival
injection  of  bevacizumab  [35,40-43],  and  a  reduction  in
neovascular glaucoma after intracameral injection [44,45].
Intravitreal injection is currently the most common route of
treatment for age-related macular degeneration with choroidal
neovascularization [46].
Studies have shown that there is a balance in the cornea
between  angiogenic  molecules  such  as  VEGF  and
erythropoietin (EPO) and anti-angiogenic molecules such as
pigment epithelium derived factor (PEDF). Angiogenesis and
erythropoiesis represent adaptive responses to hypoxia and
are  upregulated  in  ischemic  conditions.  PEDF,  a  50-kDa
protein secreted by the retinal pigment epithelium, inhibits the
growth of new blood vessels, most likely via the PI3K/Akt
pathway, and shows an inverse pattern of expression to VEGF
and EPO [47]. Intravitreal bevacizumab injections have been
found to reduce aqueous VEGF and increase PEDF in patients
with choroidal neovascularization secondary to age-related
macular degeneration or pathologic myopia [48].
Insulin-like  growth  factor  (IGF)-1  and  its  receptor,
IGF-1R,  have  also  been  implicated  in  choroidal
neovascularization. IGF-1 participates in angiogenesis of the
developing  retina  in  newborns  [49].  Although  it  failed  to
enhance endothelial tube formation in vitro [50], it increased
VEGF secretion in cultured ARPE-19 cells [51]. Accordingly,
IGF-1R inhibitors may be useful tools in the treatment of
conditions associated with neovascularization.
The  proangiogenic  CXC  chemokine  macrophage
inflammatory  protein  (MIP)-2  induces  endothelial  cell
chemotaxis  [52]  and  promotes  angiogenesis  in  cancer
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2327conditions [53]. MIP-2 regulates the production of VEGF, and
like  VEGF,  it  mediates  the  regulation  of  corneal
neovascularization caused by bacterial infection [54]. One
study  showed  that  following  infection,  both  the  corneal
resident cells and infiltrating neutrophils produced MIP-2 and
VEGF,  and  the  significantly  high  levels  of  both  genes
paralleled the extensive corneal neovascularization seen at
later stages of the disease. Anti-MIP-2 antibody treatment
significantly  reduced  both  VEGF  expression  and  corneal
neovascularization  [54].  However,  these  findings  are
controversial.  Others  have  reported  that  following  alkali
injury in mice, the injection of neutralizing anti-mouse MIP-2
antibodies had no effect on corneal neovascularization [55].
The present study was conducted in a mouse model of
chemically-induced corneal neovascularization. The aim of
the  study  was  to  evaluate  the  effect  of  treatment  with
bevacizumab  by  three  different  routes  of  injection
(subconjuctival,  intracameral,  and  intravitreal).  We
characterized the damage clinically and angiographically and
measured  the  areas  of  neovascularization  in  vivo  and  on
histological and flat-mount sections. Molecular analysis of
changes in the levels of expression of angiogenesis-related
genes  was  performed  with  real-time  polymerase  chain
reaction  (PCR).  In  addition,  given  the  low  affinity  of
bevacizumab to murine VEGF [56], we also qualitatively
investigated the ocular effects of bevacizumab treatment in a
rabbit model.
METHODS
Animals: The effect of injection route of bevacizumab on
corneal neovascularization following a chemical burn was
investigated in 119 C57BL57 male mice aged 6–8 weeks and
weighing  20–25  g  (Harlan  Laboratories,  Jerusalem).  In
addition, the qualitative effect of treatment was studied in six
female outbreed commercial rabbits (Kfar HaNagid, Israel)
weighing 2–2.5 kg and aged six months.
All  protocols  were  conducted  in  accordance  with  the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research and were approved and monitored by the
Animal  Care  Committee  of  Rabin  Medical  Center.  The
animals were housed under a 14 h:10 h light-dark cycle with
standard chow and water ad libitum.
Induction of corneal neovascularization:
Mouse  model—The  mice  were  placed  under  general
anesthesia by intramuscular injection of combined ketamine/
xylazine (80 mg/kg and 8 mg/kg, respectively) supplemented
by topical anesthesia (proparacaine hydrochloride 0.5%). The
silver nitrate cauterization technique described by Mahoney
and  Waterbury  [57]  was  used  to  induce  corneal
neovascularization. Briefly, under the operating microscope,
an applicator stick coated with 75% silver nitrate and 25%
potassium nitrate with a diameter of 1.8 mm was pressed on
the central right cornea of each animal for 10 seconds. Excess
chemical reagent was removed by rinsing the eyes with 5 ml
of balanced salt solution (NaCl 0.9%). The left eyes were not
injured and served as controls. To increase the reproducibility
of the injuries, a single investigator (N.G.-C.) cauterized all
animals.
Rabbit model—A similar technique was used to induce
central chemical burn in the right eye of the rabbits.
Bevacizumab injections:
Mouse  model—Immediately  after  cauterization,  the
treated mice (n=63, Table 1) received a single injection of
bevacizumab (25 mg/ml) into the right eye via a Hamilton
syringe with a 30-gauge tip (Hamilton, Reno, NV). Injections
were delivered by one of three routes: subconjuctival: 2.5 mg/
0.1 ml (n= 22), intravitreal: 0.75 mg/0.03 ml (n= 20), or
intracameral: 0.5 mg/0.02 ml (n= 21). The left eyes were
untreated.
Rabbit  model—Bevacizumab  was  injected  into  the
anterior chamber immediately after induction of chemical
burn to the rabbit cornea (n=6).
Digital  photographs:  To  quantify  the  extent  of
neovascularization, photographs were taken at 2, 4, 8, 10 and
14 days after cauterization in the mice and rabbits with a
Canon  A610  digital  camera  attached  to  a  slit-lamp
microscope. The corneal surface area containing neovascular
vessels was measured on the photographs as the percentage
TABLE 1. MICE USED IN THE STUDY.
Procedure
Model-untreated
(n=56)
Bevacizumab-treated (n=63)
SC (n=22) IV (n=20) IC (n=21) Total (n=63)
In vivo digital photographs 32 20 18 19 57
India ink (flat cornea) 2 2 2 2 6
Fluorescein angiography 4 - - - -
Histology (H&E) 8 8 8 8 24
Corneal flat mounts 4 - - - -
Antibody staining - - 4 - 4
Real-time PCR 10 12 12 19 57
Several mice underwent more than one procedure. Abbreviations are: SC-subconjunctival, IV-intravitreal, IC-intracameral.
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on each cornea using a public domain Java image processing
program  developed  at  the  National  Institutes  of  Health,
Washington, D.C.
India ink perfusion: Mice (n=8; six treated, two untreated)
were anesthetized with ketamine/xylazine on day 10 after
corneal cauterization and perfused with 1 ml of waterproof
Sanford-Higgins  Black  India  Ink  for  drawing  (Sanford,
Oakbrook, IL). The eyes were removed and the corneas (with
limbal regions) were isolated, radial-cut and flat-mounted.
The samples were reviewed under a light microscope for new
vessels and photographed.
Fluorescein  angiography:  To  confirm  the  growth  of  new
pathological vessels, untreated mice (n=4) were anesthetized
for  fluorescein  angiography  on  day  10  after  corneal
cauterization. Animals were injected with 0.04 ml of 25%
sodium fluorescein (AK-Fluor 25% AMP; Akorn, Decatur,
IL), and the procedure was performed using a digital fundus
camera (Topcon TRC 50x, Farmingdale, NY). Thereafter, the
mice  were  euthanized,  and  flat  corneas  filled  with  the
fluorescein dye were analyzed under the microscope.
Histological study: After euthanization of both the treated and
untreated groups (n=24, Table 1), both eyes from each subject
were enucleated and embedded in paraffin, and 5-μm thick
sagittal sections were stained with hematoxylin and eosin and
examined under a light microscope. The disruption of the
corneal structure and the presence of neovascularization were
documented. Measurements were performed in triplicate at 20
μm intervals at all corneal thicknesses.
Corneal  flat-mount  immunostaining:  Mice  (n=4)  were
euthanized by CO2 inhalation on day 8 after cauterization to
study the endothelium. The eyes were enucleated and the
corneas  isolated  and  fixed  in  4%  formaldehyde.
Immunochemistry staining for the endothelial marker was
performed to detect pathological blood vessels in the cornea.
Briefly,  corneal  flat-mounts  were  rinsed  several  times  in
phosphate buffered saline, blocked with 1% bovine serum
albumin,  stained  with  Rat  Anti-Mouse  Pecam-1  [CD31]
monoclonal antibody overnight (1:100; CBL1337, Chemicon,
Bellirica, MA), washed three times for 5 min with PBS and
stained with goat anti-rat IgG-1 for 1 h at room temperature
(1:200; A11077, Molecular Probes, Eugene, OR).
Antibody staining for intraocular bevacizumab: Eyes (n=4)
were enucleated 1 day after intravitreal injection, fixed in
formalin,  embedded  in  paraffin  wax,  sectioned  and
deparaffinized.  Donkey  anti-human  Cy3-labeled  IgG
(dilution  1:100;  69901,  Jackson  ImmunoResearch
Laboratories, West Grove, PA) was used for bevacizumab
detection. This polyclonal antibody binds to epitopes of both
Fc and Fab portions of human IgG. Untreated control eyes
were  stained  in  the  same  way.  The  sections  were  then
examined with a confocal microscope (Zeiss 510).
Molecular analysis: Corneal tissue was dissected and snap-
frozen in liquid nitrogen. Total RNA was isolated using a
TRIzolTM reagent (Invitrogen, Life Technologies, Carlsbad,
CA),  according  to  the  manufacturer’s  protocol,  and  then
reverse-transcribed  into  cDNA  using  random  hexamers
(Bioline, London, UK) and Moloney murine leukemia virus
(M-MLV)-reverse transcriptase (Promega, Madison, WI).
Two-stage  real-time  quantitative  PCR  (Sequence
Detection  System,  Prism  7900;  Applied  Biosystems,  Inc.,
Foster City, CA) was applied to evaluate the genes encoding
VEGF, IGF-1, MIP-2, PEDF, and beta actin (ACTB) after
cauterization (for primer list, see Table 2). Mouse β-actin was
used to normalize the cDNA input levels. Reactions were
performed in a 20 µl volume containing 4 µl cDNA, 0.5 µM
each of forward and reverse primers and buffer included in
the master mix (SYBR® Green I; Applied Biosystems, Inc.).
Duplicate reactions were performed for each gene to minimize
individual tube variability, and an average was taken for each
time  point.  Threshold  cycle  efficiency  corrections  were
calculated, and melting curves were obtained using cDNA for
each individual gene PCR assay.
PCR  cycling  conditions  consisted  of  an  initial
denaturation step of 95 °C for 10 min followed by 40 cycles
of 15 s denaturation at 95 °C and 1 min of annealing and
extension  at  60  °C.  Standard  curves  were  obtained  using
untreated mouse cDNA for each gene PCR assay. The results
were  quantified  using  a  comparative  threshold  cycle  (Ct)
method, also known as the 2-ΔΔCt method [58], where: ΔΔCt =
ΔCt(sample) – ΔCt (reference gene).
For  each  treatment,  the  levels  of  expression  in  the
cauterized  right  eye  were  compared  to  the  untreated  eye,
which served as an internal control.
Statistical  analysis:  Differences  between  groups  were
analyzed using an unpaired Student t-test. Significance was
set at p<0.05.
TABLE 2. LIST OF PRIMERS.
Gene Forward (5’-3’) Reverse (3’-5’)
VEGF CACGACAGAAGGAGAGCAGAA CGCTGGTAGACGTCCATGA
MIP-2 CTGTATTCCCCTCCATCGTG CTCGTCACCCACATAGGAGTG
IGF-1 AGAGACCCTTTGCGGGGC CGGATAGAGCGGGCTGCTT
PEDF GGACTCTGATCTCAACTGCAAGA GGAGGAAGAAGATGATGCTCATAC
ACTB TAGGCACCAGGGTGTGATGGT CATGTCGTCCCAGTTGGTAACA
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Area of neovascularization:
Mouse model—The mean burn area in the center of the
cornea measured 10% of the total corneal area in the untreated
mice.  In  all  mice  subjected  to  chemical  burn,  corneal
neovascularization started on day 2 and reached its maximum
on  days  8–10.  We  calculated  the  relative  area  of  corneal
neovascularization as 11.24% (±7.0) on day 2, 19.70% (±8.9)
on day 4, 47.42% (±25.4) on day 8 and 50.62% (±24.7) on day
10.  Spontaneous  regression  of  the  neovascularization  was
detected  on  day  14,  when  the  calculated  area  of
neovascularization was 26.98% (±19.9) of the corneal area
(Table 3).
In  the  bevacizumab-treated  mice,  the  relative  area  of
neovascularization in the corneas was lower at all time points
than in the untreated, cauterized mice (Table 3). Differences
between the groups were significant on days 8, 10 and 14
(p<0.005).
Qualitative  rabbit  model—In  the  rabbits  (n=6),  the
mean burn area measured 10% of the corneal area of the
untreated  eyes.  Neovascularization  was  induced  by  the
chemical burn in all rabbits starting on day 2 and achieved its
maximum on day 8. Neovascularization covered less than
20% of the corneas at sacrifice (Figure 1).
The  intracameral  (anterior  chamber)  injection  of
bevacizumab reduced the neovascularization in the rabbits.
Moreover, the limbal congestion noted in the untreated model
did not develop.
Route of injection: All three injection routes of bevacizumab
— intravitreal, intracameral and subconjuctival — reduced
growth of new abnormal vessels in the mice (Figure 2H-J).
However,  intraocular  injections  were  the  most  effective
(p<0.005, 8 and 10 days after injury).
Fluorescein  angiography:  In  the  neovascular  model,
following  an  intraperitoneal  injection  of  fluorescein,
angiography demonstrated new vessels in the cornea on day
8 (maximum growth). The vessels were located at 360 degrees
along  the  periphery  cornea,  arising  from  the  limbus  and
extending towards the central scar. The new vessels showed
early leakage that increased with time (Figure 2C-E).
Immediately following fluorescein angiography, the eyes
were enucleated for flat-mount studies to validate the area of
neovascularization (Figure 2F-G). Intraluminal fluorescein
dye analysis demonstrated peripheral neovascularization of
about 50% of the corneal area at 8 days after cauterization
(Figure 2G).
India  ink  perfusion:  Flat-mount  corneal  studies  following
perfusion  with  India  ink  were  conducted  10  days  after
cauterization.  Patent  vessels  were  noted  in  the  corneal
periphery covering 50% of the corneal area (Figure 2L). After
bevacizumab treatment, the area of neovascularization was
significantly reduced (Figure 2M-O).
Histology: Histological sections stained with hematoxylin and
eosin showed scarring in the epithelial and anterior stroma of
the central corena after cauterization. New pathological blood
vessels were located in the superficial stroma, filled with
erythrocytes (Figure 3). Neovascularization was detected in
both untreated and treated corneas.
Staining for endothelial marker: Blood vessels in the flat-
mount corneas were stained with CD31, as shown in Figure
4. Staining was negative for endothelial marker in the control
avascular cornea.
Staining  for  intraocular  bevacizumab:  One  day  after
intravitreal injection of 0.75 mg in 0.03 ml of bevacizumab,
staining  with  anti-human  Cy3TM  conjugated  affine  pure
TABLE 3. RELATIVE AREA OF NEOVASCULARIZATION (IN VIVO MEASUREMENT BY IMAGEJ).
Time
(days)
Model of corneal
neovascularization
(n=32)
Bevacizumab treated (n=57)
No
treatment Total (n=57)
Intraocular injection (n=37) Sub-conjuctival
injection
(n=20)
Intra-cameral
      (n=19)
Intra-vitreal
(n=18)
2 11.24±7.02
10.98±8.79
p=0.88
14.41±2.98
p=0.06
11.05±2.49
p=0.91
7.05±2.88
*p=0.012
4 19.70±8.96
14.76±8.79
*p=0.01
16.51±6.27
p=0.18
14.68±5.05
p=0.03
15.69±6.00
p=0.09
8 47.42±25.45
27.10±21.84
*p=0.0001
26.28±6.53
*p=0.005
23.51±6.51
*p=0.001
32.16±15.21
p=0.04
10 50.62±24.74
28.29±20.92
*p=0.001
19.86±1.23
*p=0.0004
24.20±14.87
p=0.02
39.73±14.51
P=0.27
14 26.98±19.90
10.97±10.84
*p=0.002
5.28±5.90
*p=0.01
4.16±6.43
*p=0.009
23.48±17.32
p=0.68
The asterisk indicates a p<0.05.
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the anterior chamber, filtrating into the cornea (Figure 5B).
No  such  findings  were  detected  in  the  negative  controls
(cauterization without bevacizumab treatment; Figure 5A).
Molecular analysis:
Vascular Endothelial Growth Factor—In the untreated
eyes,  VEGF  expression  peaked  on  day  10  and  decreased
slightly on day 14, in line with the clinical observations. The
bevacizumab-treated eyes showed a slight increase in VEGF
expression from day 2 (2.49 fold) to day 14 (3.43 fold) (Table
4, Figure 6A).
Pigment Epithelium Derived Factor—PEDF showed
an inverse pattern of expression to VEGF. After untreated
cauterization, PEDF gene expression was 0.35 on day 2, with
a mild increase toward baseline until day 10; by day 14,
expression measured 3.54 fold. With bevacizumab treatment,
PEDF levels decreased on day 2 (0.44 fold), followed by a 2-
fold increase on days 8 and 10, and a 5.48-fold increase on
day 14 (Table 4, Figure 6B).
Insulin-Like Growth Factor-1—In the untreated eyes,
IGF-I expression increased on day 2, returned to baseline on
day  8  and  increased  again  on  day  14  (2.88  fold).  With
bevacizumab  treatment,  levels  decreased  on  day  2,
significantly increased on day 8 (3.6 fold), peaked on day 10
(5.4-fold) and decreased on day 14 (1.94 fold; Table 4, Figure
6C).
Macrophage-Inflammatory  Protein-2—MIP-2
expression significantly increased in both the untreated and
treated mice on day 2 and then dropped to near-normal levels
by day 14. However, in the treated group, the levels increased
to over 300 fold, followed by a reduction to 200 fold. In the
untreated group, the maximal level achieved was only 166
fold (Table 4, Figure 6D).
DISCUSSION
The  avascular,  transparent  nature  of  the  cornea  makes  it
possible for researchers to detect and measure new blood
vessel development [59]. The present study molecularly and
histologically  characterized  a  mice  model  of  corneal
neovascularization and measured the effect of bevacizumab
treatment on the appearance of new vessels and the changes
in angiogenesis-related genes using three different routes of
injection: intravitreal, intracameral or subconjuctival.
We  found  that  neovascularization  appeared  two  days
after the chemical burn was induced, which then progressed
from the limbal vascular plexus toward the cauterization site
in the central cornea. Maximal vessel growth was observed
8–10 days after injury, with spontaneous regression thereafter.
Figure 1. Corneal neovascularization in
rabbits.  A-B:  Clinical  appearance  of
neovascularization in a rabbit cornea 10
days  (peak)  after  chemical  burn
induction. Note the central scar (yellow)
covering  approximately  10%  of  the
corneal  area.  C-D:  Intracameral
bevacizumab-treated cornea at 10 days.
Note the reduced neovascularization.
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2331These findings are in agreement with other reports of corneal
neovascularization in mouse [3], rat [60], rabbit [17] and
guinea pig [61] models. On day 10, the maximal area of
neovascularization in our study measured 51% of the corneal
area, compared to 23.5% in the guinea pig after 10 days [61],
and 72% [34], 68% [60] and 63% [20] in rats after one week.
The reason for the lower rate in the guinea pig is unclear,
though it is probably unrelated to the different corneal size.
In  vivo  analysis  of  our  model  with  fluorescein
angiography demonstrated early leakage. Analysis with India
ink showed the complex of the vessel tree in the flat-mount
cornea.  Histologically,  the  vessels  were  located  in  the
superficial  stroma,  resembling  the  pathology  described  in
human corneas following keratoplasty [62].
A single injection of bevacizumab reduced the corneal
neovascularization relative to the untreated, injured mouse
model.  The  effect  was  greater  with  the  intraocular  route
(anterior chamber or vitreous) than with the subconjuctival
route. The effect of a subconjuctival bevacizumab injection
has been previously investigated in rat [63], guinea pig [61]
Figure 2. Clinical appearance of neovascularization in a mouse cornea. Comparison between normal eye, without blood vessels on the cornea
(A) and 8 days following cauterization without treatment, with high level of neovascularization (B). Less blood vessels observed after
bevacizumab treatment by (H) intravitreal injection, (I) intracameral injection or (J) subconjunctival injection at the same time point.
Fluorescein angiography 8 days after chemical burn induction showing (C) early leakage and (D-E) increased late leakage. Flat mount cornea
of the control mouse showing transparent cornea without blood vessels (F). In the neovascular corneal model, studies with fluorescein dye
(G) and India ink (K, black) reveal new vessels 8 days after induction of chemical burn, compared to the control avascular cornea (K), and a
reduced level of NV detected following bevacizumab treatment (M-O).
Figure 3. Histology analysis using hematoxylin-eosin staining. No blood vessels detected in the normal cornea (A). Following cauterization,
development of the scar (arrow) was observed in the epithelial and anterior stroma of the center cornea (B). New pathological blood vessels
(C) were located in the superficial stroma, filled with erythrocytes (*).
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2332and rabbit models [21,43,64] and in humans [41]. Hurmeric
et  al.  [61]  noted  a  significant  reduction  in  corneal
neovascularization  when  bevacizumab  was  injected
subconjuctivally immediately after cauterization and again on
day 3 after injury. Delayed injections (days 3 and 5) had a
significantly weaker effect. The adjuvant injection as well as
species differences may account for the superior results of this
study  compared  to  ours.  In  an  earlier  rabbit  model  [43],
subconjunctival injection of bevacizumab caused significant
inhibition of corneal neovascularization.
The intravitreal route is commonly used nowadays, with
only minor complications, in patients who require repeated
injections  for  age-related  macular  degeneration  [46],  Best
disease [65] or macular edema of central retinal vein occlusion
[66].  In  the  present  study,  intravitreal  injection  of
bevacizumab was associated with a 50% reduction in corneal
neovascularization  compared  to  the  untreated  model
(p<0.001;  Figure  2).  There  were  no  injection-related
complications. Surprisingly, intravitreal injection had a better
effect on regression of the corneal neovascularization than
injections into the anterior chamber, which come into contact
with the cornea. However, the difference was not statistically
significant.  Immunostaining  was  performed  to  better
understand  the  location  of  the  intravitreally-injected
Figure 4. Corneal flat-mount immunostaining for endothelial marker. Flat-mount corneas were stained with endothelial marker using anti-
CD31 antibody. No positive staining detected in a control mouse (avascular cornea; A) compared to blood vessels detected in the flat mount
cornea  8 days after cauterization (red staining; B).
Figure 5. Immunostaining for intraocular bevacizumab. No staining was detected using Anti-human antibody labeled with CY3 dye in an
untreated mouse after chemical burn injury (A) without bevacizumab injection. Bevacizumab staining identified in the anterior chamber,
filtrating into the cornea, following intraocular injection one day after injury (B).
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2333bevacizumab, and it revealed that the agent was in the anterior
chamber and penetrating the cornea as early as day 2 (Figure
5). Accordingly, others reported that ranibizumab (Lucentis)
could  be  detected  in  the  aqueous  humor  three  days  after
intravitreal administration [67]. These authors attributed the
drug’s  effectiveness  to  the  shift  from  the  vitreous  to  the
aqueous humor, and possibly to the presence of the drug in
the anterior chamber one day after induction of injury [67].
We  assumed  that  in  our  study,  bevacizumab  reached  the
corneal stroma by passive diffusion. Chen et al. [43] reported
positive  staining  for  bevacizumab  in  the  corneal  stroma
between  3-14  days  following  injury  induction  in  several
different rabbit models of corneal neovascularization. They
suggested  that  bevacizumab  may  be  useful  in  preventing
corneal neovascularization in the acute phase of various kinds
of corneal inflammation. In a study of the effectiveness of
bevacizumab in a rabbit model of retinal detachment, Dib et
al.  [68]  detected  subretinal  drug  molecules  2  h  after
intravitreal injection. Given the absence of any retinal holes
or tears, they too attributed their findings to a mechanism of
diffusion throughout the retinal layers.
Bevacizumab only partially inhibited neovascularization
in our mouse model compared to its almost 90% inhibition of
choroidal neovascularization in human eyes. The difference
might be species-related, as rat, rabbit and guinea pig models
all showed a better response to treatment. Yu et al. [41] found
bevacizumab to be species-specific, with weak interaction
with  murine  VEGF  relative  to  human  VEGF  due  to
differences in the spatial molecular structure.
Although  our  qualitative  analysis  yielded  a  better
response  to  bevacizumab  in  rabbits  than  in  mice,  we
nevertheless  found  a  consistent  trend  of  a  decrease  in
neovascularization  following  bevacizumab  injection  by
different routes. In the wake of advances in the treatment of
eye disease involving pathologic angiogenesis, interest has
been directed to developing reliable and reproducible animal
models [69]. Models of anterior segment neovascularization
include the corneal micropocket assay, which is used to study
the influence of specific molecules/proteins in angiogenesis,
and suture-induced or corneal chemical injury, as in our study,
which more closely mimics the complex nature of human
disease [69]. The mouse model of corneal neovascularization
is well-recognized as a reliable and valid model of all diseases
that involve neovascularization [69]. The cornea is also well-
visualized  and  easily  accessible  for  qualitative  and
quantitative  measurement.  Accordingly,  we  were  able  to
TABLE 4. GENE EXPRESSION IN THE UNTREATED AND BEVACIZUMAB-TREATED CORNEAS.
Time point
Gene
2 days 8 days 10 days 14 days
Model Treated Model Treated Model Treated Model Treated
VEGF
2.98
(±0.04)
2.49
(±1.95)
3.80
(±5.50)
2.96
(±2.78)
4.10
(±3.30)
3.27
(±2.32)
3.64
(±2.41)
3.43
(±1.71)
PEDF
0.35
(±0.48)
0.44
(±0.09)
0.65
(±0.19)
2.0
(±0.7)
0.84
(±0.08)
1.78
(±0.78)
3.54
(±0.37)
5.48
(±3.97)
IGF-1
1.65
(±1.65)
0.66
(±0.45)
0.90
(±0.31)
3.60
(±1.76)
1.37
(±0.85)
5.41
(±4.96)
2.88
(±0.68)
1.94
(±0.89)
MIP-2 166.43 332.53 75.25 197.11 76.25 170.83 11.45 4.63
Figure  6.  Molecular  analysis  of  gene
expression  levels  after  chemical
cauterization  in  the  untreated  and
bevacizumab  treated  mice.  VEGF
expression  up-regulated  in  all  time
points, with a slight decrease following
bevacizumab  treatment  (A).  PEDF
showed an inverse pattern of expression
to  VEGF  (B).  IGF-1  expression
increased  between  days  8  and  10
following injury, with a higher level in
the  bevacizumab  treated  group  (C).
MIP-2  expression  significantly
increased  in  both  the  untreated  and
treated mice on day 2 and then dropped
to near-normal levels by day 14, with
higher level in the bevacizumab treated
eyes (D).
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2334characterize the relative changes in the angiogenesis-related
genes  and  to  identify  new  aspects  of  the  mechanisms
underlying corneal neovascularization in the mice.
VEGF is required for angiogenesis [70]. In our model,
there was an upregulation of VEGF mRNA expression in both
the untreated and bevacizumab-treated mice, although there
was slightly less in the treated group (Table 4). Yan et al.
[71]  conducted  an  in  vivo  study  of  VEGF  and  TSP2
expression after corneal alkali burn. They found that the level
of  VEGF  increased  at  6  h  after  injury  and  reached  its
maximum at 12 h. The level then increased again to additional
peaks at 96 h and 192 h. The VEGF-positive reaction was
concentrated  mainly  in  the  corneal  stroma.  This  is  in
accordance with our detection of bevacizumab in the corneal
stroma using immunohistochemical staining (Figure 5). In
contrast,  the  expression  of  PEDF  in  the  untreated  mice
decreased until the late stages of angiogenesis, and peaked
only at 14 days following cauterization during the process of
wound healing (Table 4). In the treated mice, the expression
of PEDF decreased early and then increased progressively
until  day  14.  These  findings  reflect  the  complicated
interaction, with many factors involved in the promotion and
inhibition of vascularization in vivo [72-74].
IGF-1 is known to induce angiogenesis [75] and may
explain  the  upregulation  at  the  early  state  of
neovascularization  process.  In  our  model,  IGF-1  was
upregulated early in the untreated mice, with higher levels in
the  bevacizumab-treated  group  than  at  all  the  other  later
points. A previous study that used an ischemic mouse model
also reported an increase in IGF-1 three days following injury
[76]. Eight days after cauterization, there was a slight change
in IGF-1 expression in the untreated mice, compared to a 3.6-
fold increase in the bevacizumab-treated group. We assume
that  when  VEGF  was  neutralized  by  bevacizumab,  other
proangiogenic factors, such as IGF-1, came into play.
MIP-2 is the murine analog of IL-8, a member of the
proinflammatory C-X-C family of cytokines that activates the
release of neutrophils during inflammation. IL-8 also serves
as a proangiogenic factor during corneal neovascularization.
Similarly to IGF-1, we found an immediate, early increase in
MIP-2 mRNA expression after chemical injury, which was
greater  in  the  bevacizumab-treated  than  in  the  untreated
group. This finding may also be a result of the inhibition of
VEGF.  This  finding  is  consistent  with  other  studies  of
molecular expression during angiogenesis [77-79], but is not
consistent with the conclusion of Lu et al. [55]. In this study,
the  authors  used  a  similar  murine  model  of  corneal
neovascularization  and  concluded  that  although  MIP-2
mediated  neutrophil  infiltration  to  the  corneal
neovascularization, it made only a minor contribution to its
development. A reduction in inflammatory cell infiltration of
chemically  burned  rat  corneas  following  bevacizumab
injection was also reported by Oh et al. [40]. However, they
noted  a  reduction  in  the  expression  of  various  cytokines,
namely  interleukin-2  and  -6  and  interferon-gamma.  It  is
noteworthy that in this study, bevacizumab treatment led to
only a borderline reduction in corneal neovascularization.
In summary, bevacizumab treatment partially inhibits the
progressive corneal neovascularization induced by chemical
injury in a mouse model. Treatment via the intraocular route
is more effective than the subconjuctival (periocular) route.
The clinical findings are compatible with the angiographic
and  histologic  findings,  and  are  supported  by  molecular
analysis  showing  changes  in  the  expression  of  pro-
angiogenesis  genes  after  treatment.  Further  studies  of  the
molecular  mechanisms  involved  in  corneal
neovascularization are needed in the animal models used in
this study and in other animal models as well. The ability to
directly  block  target  proteins  or  peptides  or  signaling
pathways holds significant promise for the development of
new, targeted anti-angiogenic therapies as well as for the
optimization  of  existing  anti-angiogenic  drugs  or
polypeptides [11].
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